{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:15:16Z","timestamp":1783318516678,"version":"3.54.6"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To systematically evaluate safety signals of selective serotonin reuptake inhibitors (SSRIs) associated with drug-induced liver injury (DILI) using the FAERS database, and to explore potential toxicological mechanisms through drug-gene interaction network analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse event data for six SSRIs (2013\u20132023) were extracted from FAERS. Descriptive analysis and disproportionality signal detection (ROR, BCPNN) were performed. Time to DILI onset and factors influencing mortality were analyzed. Network pharmacology explored drug-gene interactions. Due to the absence of individual-level clinical data in FAERS, we could not apply the updated RUCAM, the gold standard for DILI causality assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DILI reports were most frequent in patients aged 18\u201364 years and in females. Sertraline had the highest number of reports; fluvoxamine the fewest. Common signals across SSRIs included hepatocellular injury and necrosis. Fluoxetine showed unique signals for hepatic steatosis, paroxetine for chronic active hepatitis, and sertraline for severe liver failure (e.g., primary biliary cholangitis, hemorrhagic hepatic cyst). Median time to onset was within the first month of treatment. Age 18\u201344 years (OR = 3.03, 95% CI: 1.12\u20138.18) and low body weight \u226460\u00a0kg (OR = 0.45, 95% CI: 0.18\u20131.14) were significant predictors of mortality. Network analysis suggested shared mechanisms (e.g., CYP450 dysfunction, apoptosis dysregulation) and drug-specific pathways (e.g., PI3K-Akt for sertraline, IL-17 signaling for fluoxetine\/fluvoxamine).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DILI safety signals for SSRIs are most frequent within the first month of treatment, particularly in female patients. Considerable variability in hepatotoxicity profiles among SSRIs supports drug-specific monitoring. These hypothesis-generating findings provide a basis for personalized risk assessment and require confirmation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1842778","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:32Z","timestamp":1783316252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["SSRIs-induced liver injury adverse events: a data-based retrospective study and investigation of potential toxicological mechanisms"],"prefix":"10.3389","volume":"17","author":[{"given":"Jianru","family":"Wu","sequence":"first","affiliation":[{"name":"Shenzhen Institute of Pharmacovigilance and Risk Management","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chufeng","family":"Ding","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicong","family":"Ma","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoying","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qimin","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpo","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Liang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Zheng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Shenzhen Institute of Pharmacovigilance and Risk Management","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenzhen Institute of Pharmacovigilance and Risk Management","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfang","family":"Wei","sequence":"additional","affiliation":[{"name":"Shenzhen Institute of Pharmacovigilance and Risk Management","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Shenzhen Institute of Pharmacovigilance and Risk Management","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Su","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20m02747","DOI":"10.4088\/PCC.20m02747","article-title":"Side effect profiles of selective serotonin reuptake inhibitors: a cross-sectional study in a naturalistic setting","volume":"23","author":"Anagha","year":"2021","journal-title":"Prim. Care Companion CNS Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4254\/wjh.v9.i10.491","article-title":"Drug-induced liver injury: do we know everything?","volume":"9","author":"Alempijevic","year":"2017","journal-title":"World J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s42255-022-00620-x","article-title":"BMP4 and gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD\/NASH","volume":"4","author":"Baboota","year":"2022","journal-title":"Nat. Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41419-022-05282-x","article-title":"HSF2BP protects against acute liver injury by regulating HSF2\/HSP70\/MAPK signaling in mice","volume":"13","author":"Bi","year":"2022","journal-title":"Cell Death Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0165-0327(00)00199-3","article-title":"Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments","volume":"64","author":"Bilici","year":"2001","journal-title":"J. Affect Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2924","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/00004836-199901000-00014","article-title":"Atrium and paroxetine-related severe hepatitis","volume":"28","author":"Cadranel","year":"1999","journal-title":"J. Clin. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1517546","DOI":"10.3389\/fphar.2024.1517546","article-title":"Overweight and glucose\/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"15","author":"Cao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4088\/jcp.v63n0208","article-title":"Hepatotoxicity associated with the new antidepressants","volume":"63","author":"Carvajal Garc\u00eda-Pando","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00204-020-02753-y","article-title":"The role of hepatic cytochrome P450s in the cytotoxicity of sertraline","volume":"94","author":"Chen","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.6039\/j.issn.1001-0408.2023.14.17","article-title":"Meta-analysis of the influence of genetic polymorphisms on the efficacy and safety of citalopram\/escitalopram","volume":"34","author":"Chen","year":"2023","journal-title":"China Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.11569\/wcjd.v29.i16.915","article-title":"Current status and advances in drug-induced liver injury research","volume":"29","author":"Chi","year":"2021","journal-title":"World Chin. J. Dig."},{"key":"B12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1368-5031.2005.00572.x","article-title":"Toxic hepatitis associated with paroxetine","volume":"59","author":"Colakoglu","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"B13","first-page":"2449","article-title":"Acute cholestasis by fluoxetine","volume":"91","author":"Cosme","year":"1996","journal-title":"Am. J. Gastroenterol."},{"key":"B14","first-page":"178","article-title":"Risk factors and construction of a nomogram prediction model for drug-induced liver injury in cardiovascular diseases","volume":"35","author":"Cui","year":"2025","journal-title":"J. Integr. Traditional Chin. West. Med. Liver Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pnpbp.2017.06.036","article-title":"The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression","volume":"80","author":"Czarny","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol Biol. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15235","DOI":"10.1021\/acs.est.0c03998","article-title":"Probing the mechanism of hepatotoxicity of hexabromocyclododecanes through toxicological network analysis","volume":"54","author":"Dai","year":"2020","journal-title":"Environ. Sci. Technol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e000475","DOI":"10.1136\/bmjdrc-2017-000475","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA adverse event reporting system","volume":"6","author":"Fadini","year":"2018","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1176\/ajp.153.4.580a","article-title":"Hepatitis secondary to fluoxetine treatment","volume":"153","author":"Friedenberg","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4088\/jcp.v63n0304","article-title":"An open-label trial of citalopram for major depression in patients with hepatitis C","volume":"63","author":"Gleason","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1192\/bjp.153.1.130","article-title":"Fluvoxamine and hepatic function","volume":"153","author":"Green","year":"1988","journal-title":"Br. J. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3748\/wjg.v8.i6.1059","article-title":"Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma","volume":"8","author":"Guo","year":"2002","journal-title":"World J. Gastroenterol."},{"key":"B24","first-page":"364","article-title":"Symptomatic liver injury probably related to sertraline","volume":"22","author":"Hautekeete","year":"1998","journal-title":"Gastroenterol. Clin. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"16756","DOI":"10.1038\/s41598-024-67882-1","article-title":"Emodin alleviates cholestatic liver injury by modulating Sirt1\/Fxr signaling pathways","volume":"14","author":"Hu","year":"2024","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.16150\/j.1671-2870.2008.02.019","article-title":"Pathogenesis and subtype diagnosis of drug-induced liver injury","volume":"7","author":"Huang","year":"2008","journal-title":"J. Diagnostics Clin. Pract."},{"key":"B30","first-page":"75","article-title":"Pathogenic role of cellular senescence in non-alcoholic fatty liver disease","volume":"14","author":"Huang","year":"2024","journal-title":"J. Med. Diagnostics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"20420986241244585","DOI":"10.1177\/20420986241244585","article-title":"Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis","volume":"15","author":"Jiang","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/03602532.2024.2313967","article-title":"Metabolic bioactivation of antidepressants: advance and underlying hepatotoxicity","volume":"56","author":"Khalil","year":"2024","journal-title":"Drug Metab. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jhep.2018.01.003","article-title":"Hsp72 protects against liver injury via attenuation of hepatocellular death, oxidative stress, and JNK signaling","volume":"68","author":"Levada","year":"2018","journal-title":"J. Hepatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"CD012855","DOI":"10.1002\/14651858.CD012855.pub2","article-title":"Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults","volume":"5","author":"Machmutow","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Safety"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1257601","DOI":"10.1126\/science.1257601","article-title":"Uncovering disease-disease relationships through the incomplete interactome","volume":"347","author":"Menche","year":"2015","journal-title":"Science"},{"key":"B37","first-page":"3691","article-title":"Fluoxetine-induced apoptosis in hepatocellular carcinoma cells","volume":"33","author":"Mun","year":"2013","journal-title":"Anticancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.immuni.2019.11.004","article-title":"Type 1 innate lymphoid cells protect mice from acute liver injury via Interferon-\u03b3 secretion for upregulating Bcl-xL expression in hepatocytes","volume":"52","author":"Nabekura","year":"2020","journal-title":"Immunity"},{"key":"B39","unstructured":"NHSA\n          \n          \n          2023"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1111\/j.1572-0241.2001.04060.x","article-title":"Severe hepatotoxicity with jaundice associated with paroxetine","volume":"96","author":"Odeh","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-008-0111-9","article-title":"Acute hepatitis associated with use of paroxetine","volume":"3","author":"Pompili","year":"2008","journal-title":"Intern Emerg. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","article-title":"Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism","volume":"32","author":"Preskorn","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7326\/0003-4819-157-2-201207170-00006","article-title":"Escitalopram for the prevention of peginterferon-\u03b12a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial","volume":"157","author":"Schaefer","year":"2012","journal-title":"Ann. Intern Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1378090","DOI":"10.3389\/fphar.2024.1378090","article-title":"CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network","volume":"15","author":"She","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/jm201468j","article-title":"Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications","volume":"55","author":"Shen","year":"2012","journal-title":"J. Med. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-Marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/clep.s365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"","journal-title":"Clin. Epidemiology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"716648","DOI":"10.3389\/fped.2021.716648","article-title":"Cardiotoxicity in biological agent-targeted therapy for rheumatoid arthritis: ADR signal mining and analysis of food and drug administration adverse event reporting system database","volume":"9","author":"Tang","year":"2021","journal-title":"Front. Pediatr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"108040","DOI":"10.1016\/j.compbiomed.2024.108040","article-title":"Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors","volume":"170","author":"Tang","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/bcp.13593","article-title":"Drug induced liver injury with analysis of alternative causes as confounding variables","volume":"84","author":"Teschke","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/diagnostics15131588","article-title":"Drug-Induced autoimmune hepatitis: robust causality assessment using two different validated and scoring diagnostic algorithms","volume":"15","author":"Teschke","year":"2025","journal-title":"Diagn. (Basel)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(22)01012-1","article-title":"Depression in young people","volume":"400","author":"Thapar","year":"2022","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00204-020-02963-4","article-title":"Antidepressants- and antipsychotics-induced hepatotoxicity","volume":"95","author":"Todorovi\u0107 Vukoti\u0107","year":"2021","journal-title":"Arch. Toxicol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.12998\/wjcc.v10.i8.2468","article-title":"Escitalopram-induced hepatitis: a case report","volume":"10","author":"Wabont","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"B56","doi-asserted-by":"publisher","first-page":"W356","DOI":"10.1093\/nar\/gkx374","article-title":"PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/17425255.2020.1779701","article-title":"PXR-Mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches","volume":"16","author":"Wang","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.20053\/j.issn1001-5094.2023.02.005","article-title":"Advances in the regulation of hepatic lipid metabolism by nuclear receptor FXR","volume":"47","author":"Wang","year":"2023","journal-title":"Prog. Pharm. Sci."},{"key":"B59","first-page":"214","article-title":"Clinical features and prognostic risk factors in patients with drug-induced liver injury","volume":"32","author":"Wei","year":"2024","journal-title":"Chin. J. Hepatology"},{"key":"B60","volume-title":"Clinical Characteristics and Outcomes of 202 Patients with drug-induced Liver Injury . Doctoral dissertation","author":"Xu","year":"2023"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.14000\/j.cnki.issn.1008-1704.2023.09.014","article-title":"MRI characteristics associated with clinical subtypes, severity, and prognosis in 122 patients with drug-induced liver injury","volume":"28","author":"Xu","year":"2023","journal-title":"Chin. Hepatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH guidelines for the diagnosis and treatment of drug-induced liver injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol. Int."},{"key":"B63","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cej.2017.02.032","article-title":"Ozonation of antidepressant fluoxetine and its metabolite product norfluoxetine: kinetics, intermediates and toxicity","volume":"316","author":"Zhao","year":"2017","journal-title":"Chem. Eng. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842778\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T05:37:41Z","timestamp":1783316261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842778\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":63,"alternative-id":["10.3389\/fphar.2026.1842778"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1842778","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1842778"}}